BiotechTube

indomethacin

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

May 1, 2000 → Aug 1, 2005

NCT ID
NCT00432081

About indomethacin

indomethacin is a phase 3 stage product being developed by Brain Biotech for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00432081. Target conditions include Alzheimer Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)
✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
✅DonepezilEisaiApproved
✅DONEPEZIL HYDROCHLORIDEEisaiApproved
✅Donepezil HCLEisaiApproved
✅Donepezil HClEisaiApproved
✅Donepezil HydrochlorideEisaiApproved
✅AriceptEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00432081Phase 3Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
Zagotenemab + PlaceboEli LillyPhase 2
35
Donanemab + Placebo + LY3202626Eli LillyPhase 2
35
Donanemab + PlaceboEli LillyPhase 3
47
GSK4527226AlectorPhase 2
29
AL002 + PlaceboAlectorPhase 2
25
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
donanemabEli LillyPhase 2
35
ATH-1017LeonaBioPhase 2/3
20
ATH-1017 + PlaceboLeonaBioPhase 2/3
28
ATH-1017 + PlaceboLeonaBioPhase 2
25
NDX-1017 + PlaceboLeonaBioPhase 1
19
simufilamCassava SciencesPhase 2
17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
19